The joint drug procurement office of the state organization recently released the announcement of the results of the proposed national centralized drug procurement, marking the end of the seventh batch of centralized drug procurement of the state organization. According to the information of the National Medical Security Bureau, 60 drugs were successfully purchased in this centralized purchase. The average price of the selected drugs was reduced by 48%. According to the agreed purchase volume, it is estimated that 18.5 billion yuan can be saved each year. Unlike the negotiation and price negotiation of the adjustment of the medical insurance catalogue, the centralized purchase of national drugs is conducted by enterprises independently, and the same varieties are competitive. There is another set of operation mode. What is the difference between this national drug purchase and the past? What impact will it have on the development of the pharmaceutical industry? In response to these questions, the reporter interviewed relevant people. Expand the scope - involving 31 treatment categories, with an average price reduction of 48%. The public's sense of access continues to increase. The centralized purchase of drugs is to collect the actual clinical needs of medical institutions in exchange for the drugs provided by pharmaceutical enterprises at a lower price. Therefore, the varieties of each centralized purchase and the purchase volume of each variety will be adjusted according to the clinical needs. This centralized purchase involves 31 treatment categories, including drugs for common and chronic diseases such as hypertension, diabetes, anti infection and digestive tract diseases, as well as drugs for major diseases such as lung cancer, liver cancer, kidney cancer and bowel cancer. According to the price calculation before centralized purchase, the amount involved in the centralized purchase of 294 drugs in 7 batches accounts for about 35% of the annual purchase amount of chemical drugs and biological drugs in public medical institutions. This means that centralized drug procurement has become an important mode of drug procurement in public hospitals. Gu Hai, director of the health policy and management research center of Nanjing University, told the reporter that the first five batches of centralized procurement involved 218 kinds of chemical drugs, covering common diseases, chronic diseases, major diseases and rare diseases such as hypertension, coronary heart disease, diabetes, anti allergy, anti infection, gastrointestinal diseases and anti-tumor; The Sixth Batch of centrally purchased drugs was expanded from chemical drugs to biological drugs for the first time, and 16 second - and third-generation insulin were included in the scope of centralized purchase; In the first six batches, the number of drugs for digestive tract metabolism, anti infection, nervous system, cardiovascular system and anti-tumor were included. This time, we will continue to expand the encirclement on the basis of the original one, and the masses will benefit more. Compared with the average price reduction of 53% in the first six batches of national centralized procurement, the average price reduction of the drugs to be selected this time is 48%, which is "moderate" in the eyes of some people. In this regard, the relevant responsible person of the National Medical Insurance Bureau believes that the reasons come from three aspects: first, in recent years, the medical insurance department has strengthened price management, and generally speaking, the drug prices in various provinces are more transparent; Second, the provincial-level purchase with quantity is being promoted. Some varieties of this centralized purchase have been included in the local centralized purchase, and the price level has dropped before the national centralized purchase; Third, after several rounds of centralized procurement, the enterprise competition is more rational. Although the price reduction is slightly flat, the sense of gain of the masses will not be discounted in the future. This centralized purchase not only includes more new drugs, but also the prices of some drugs have dropped significantly. Taking the first-line targeted drug lenvatinib capsules for liver cancer as an example, the average price of each capsule decreased from 108 yuan to 18 yuan, and a treatment cycle could save 8100 yuan. In the field of lowering blood pressure, it was the first time that the controlled-release dosage form was included. The price of nifedipine controlled-release tablets was reduced by 58%, and that of metoprolol sustained-release tablets was reduced by 53%